These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

826 related items for PubMed ID: 15954895

  • 1. Stimulation of soluble guanylate cyclase slows progression in anti-thy1-induced chronic glomerulosclerosis.
    Wang Y, Krämer S, Loof T, Martini S, Kron S, Kawachi H, Shimizu F, Neumayer HH, Peters H.
    Kidney Int; 2005 Jul; 68(1):47-61. PubMed ID: 15954895
    [Abstract] [Full Text] [Related]

  • 2. Expression and activity of soluble guanylate cyclase in injury and repair of anti-thy1 glomerulonephritis.
    Peters H, Wang Y, Loof T, Martini S, Kron S, Krämer S, Neumayer HH.
    Kidney Int; 2004 Dec; 66(6):2224-36. PubMed ID: 15569311
    [Abstract] [Full Text] [Related]

  • 3. Enhancing cGMP in experimental progressive renal fibrosis: soluble guanylate cyclase stimulation vs. phosphodiesterase inhibition.
    Wang Y, Krämer S, Loof T, Martini S, Kron S, Kawachi H, Shimizu F, Neumayer HH, Peters H.
    Am J Physiol Renal Physiol; 2006 Jan; 290(1):F167-76. PubMed ID: 16048904
    [Abstract] [Full Text] [Related]

  • 4. Selective lymphocyte inhibition by FTY720 slows the progressive course of chronic anti-thy 1 glomerulosclerosis.
    Peters H, Martini S, Wang Y, Shimizu F, Kawachi H, Krämer S, Neumayer HH.
    Kidney Int; 2004 Oct; 66(4):1434-43. PubMed ID: 15458436
    [Abstract] [Full Text] [Related]

  • 5. Mycophenolate mofetil slows progression in anti-thy1-induced chronic renal fibrosis but is not additive to a high dose of enalapril.
    Krämer S, Loof T, Martini S, Rückert M, Wang Y, Böhler T, Shimizu F, Kawachi H, Neumayer HH, Peters H.
    Am J Physiol Renal Physiol; 2005 Aug; 289(2):F359-68. PubMed ID: 15769934
    [Abstract] [Full Text] [Related]

  • 6. Stimulation of soluble guanylate cyclase improves renal recovery after relief of unilateral ureteral obstruction.
    Wang-Rosenke Y, Mika A, Khadzhynov D, Loof T, Neumayer HH, Peters H.
    J Urol; 2011 Sep; 186(3):1142-9. PubMed ID: 21784461
    [Abstract] [Full Text] [Related]

  • 7. NO mediates antifibrotic actions of L-arginine supplementation following induction of anti-thy1 glomerulonephritis.
    Peters H, Daig U, Martini S, Rückert M, Schäper F, Liefeldt L, Krämer S, Neumayer HH.
    Kidney Int; 2003 Aug; 64(2):509-18. PubMed ID: 12846746
    [Abstract] [Full Text] [Related]

  • 8. Low-dose mTOR inhibition by rapamycin attenuates progression in anti-thy1-induced chronic glomerulosclerosis of the rat.
    Krämer S, Wang-Rosenke Y, Scholl V, Binder E, Loof T, Khadzhynov D, Kawachi H, Shimizu F, Diekmann F, Budde K, Neumayer HH, Peters H.
    Am J Physiol Renal Physiol; 2008 Feb; 294(2):F440-9. PubMed ID: 18094032
    [Abstract] [Full Text] [Related]

  • 9. Impact of biological gender and soluble guanylate cyclase stimulation on renal recovery after relief of unilateral ureteral obstruction.
    Wang-Rosenke Y, Mika A, Khadzhynov D, Loof T, Neumayer HH, Peters H.
    J Urol; 2012 Jul; 188(1):316-23. PubMed ID: 22608751
    [Abstract] [Full Text] [Related]

  • 10. Stimulation of soluble guanylyl cyclase inhibits mesangial cell proliferation and matrix accumulation in experimental glomerulonephritis.
    Hohenstein B, Daniel C, Wagner A, Stasch JP, Hugo C.
    Am J Physiol Renal Physiol; 2005 Apr; 288(4):F685-93. PubMed ID: 15561976
    [Abstract] [Full Text] [Related]

  • 11. Vas deferens smooth muscle responses to the nitric oxide-independent soluble guanylate cyclase stimulator BAY 41-2272.
    da Silva FH, Claudino MA, Báu FR, Rojas-Moscoso JA, Mónica FZ, De Nucci G, Antunes E.
    Eur J Pharmacol; 2012 Aug 05; 688(1-3):49-55. PubMed ID: 22634166
    [Abstract] [Full Text] [Related]

  • 12. Activators and stimulators of soluble guanylate cyclase counteract myofibroblast differentiation of prostatic and dermal stromal cells.
    Zenzmaier C, Kern J, Heitz M, Plas E, Zwerschke W, Mattesich M, Sandner P, Berger P.
    Exp Cell Res; 2015 Nov 01; 338(2):162-9. PubMed ID: 26410556
    [Abstract] [Full Text] [Related]

  • 13. S1P modulator FTY720 limits matrix expansion in acute anti-thy1 mesangioproliferative glomerulonephritis.
    Martini S, Krämer S, Loof T, Wang-Rosenke Y, Daig U, Budde K, Neumayer HH, Peters H.
    Am J Physiol Renal Physiol; 2007 Jun 01; 292(6):F1761-70. PubMed ID: 17356129
    [Abstract] [Full Text] [Related]

  • 14. Nitric oxide-independent stimulation of soluble guanylate cyclase with BAY 41-2272 in cardiovascular disease.
    Boerrigter G, Burnett JC.
    Cardiovasc Drug Rev; 2007 Jun 01; 25(1):30-45. PubMed ID: 17445086
    [Abstract] [Full Text] [Related]

  • 15. Nitric oxide-independent activation of soluble guanylate cyclase by BAY 60-2770 in experimental liver fibrosis.
    Knorr A, Hirth-Dietrich C, Alonso-Alija C, Härter M, Hahn M, Keim Y, Wunder F, Stasch JP.
    Arzneimittelforschung; 2008 Jun 01; 58(2):71-80. PubMed ID: 18412020
    [Abstract] [Full Text] [Related]

  • 16. Increased cyclic guanosine monophosphate synthesis and calcium entry blockade account for the relaxant activity of the nitric oxide-independent soluble guanylyl cyclase stimulator BAY 41-2272 in the rabbit penile urethra.
    Toque HA, Antunes E, Teixeira CE, De Nucci G.
    Urology; 2008 Sep 01; 72(3):711-5. PubMed ID: 18359064
    [Abstract] [Full Text] [Related]

  • 17. Evaluation of the relaxant effect of the nitric oxide-independent soluble guanylyl cyclase stimulator BAY 41-2272 in isolated detrusor smooth muscle.
    Báu FR, Mónica FZ, Priviero FB, Baldissera L, de Nucci G, Antunes E.
    Eur J Pharmacol; 2010 Jul 10; 637(1-3):171-7. PubMed ID: 20399768
    [Abstract] [Full Text] [Related]

  • 18. Rosuvastatin is additive to high-dose candesartan in slowing progression of experimental mesangioproliferative glomerulosclerosis.
    Krämer S, Kron S, Wang-Rosenke Y, Loof T, Khadzhynov D, Morgera S, Kawachi H, Shimizu F, Martini S, Neumayer HH, Peters H.
    Am J Physiol Renal Physiol; 2008 Apr 10; 294(4):F801-11. PubMed ID: 18216152
    [Abstract] [Full Text] [Related]

  • 19. The Novel, Clinical-Stage Soluble Guanylate Cyclase Activator BI 685509 Protects from Disease Progression in Models of Renal Injury and Disease.
    Reinhart GA, Harrison PC, Lincoln K, Chen H, Sun P, Hill J, Qian HS, McHugh MC, Clifford H, Ng KJ, Wang H, Fowler D, Gueneva-Boucheva K, Brenneman JB, Bosanac T, Wong D, Fryer RM, Sarko C, Boustany-Kari CM, Pullen SS.
    J Pharmacol Exp Ther; 2023 Mar 10; 384(3):382-392. PubMed ID: 36507845
    [Abstract] [Full Text] [Related]

  • 20. Effects of BAY 41-2272, an activator of nitric oxide-independent site of soluble guanylate cyclase, on human NADPH oxidase system from THP-1 cells.
    Borges de Oliveira-Junior E, Thomazzi SM, Rehder J, Antunes E, Condino-Neto A.
    Eur J Pharmacol; 2007 Jul 12; 567(1-2):43-9. PubMed ID: 17499238
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 42.